Scancell (LON:SCLP) Trading 29.8% Higher – Still a Buy?

Scancell Holdings plc (LON:SCLP) traded up 29.8% on Monday . The company traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.14). 10,537,342 shares traded hands during trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Stock Up 29.8 %

The firm has a fifty day simple moving average of GBX 8.43 and a 200-day simple moving average of GBX 10.88. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The company has a market capitalization of £113.93 million, a P/E ratio of -16.86 and a beta of 0.35.

Scancell (LON:SCLP) last posted its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. On average, equities research analysts expect that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.